World's Best Scientists 2026 revealed!
Jeffrey A. Gelfand

Jeffrey A. Gelfand

D-Index & Metrics

Microbiology

D-Index
51
Citations
11549
World Ranking
4297
National Ranking
1657

Jeffrey A. Gelfand publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Jeffrey A. Gelfand sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 137 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Jeffrey A. Gelfand D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Jeffrey A. Gelfand sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 51 D-Index — 23rd percentile

23% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2007 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Jeffrey A. Gelfand is affiliated with Harvard University in the United States. Their research primarily focuses on medicine, with a significant emphasis on infectious diseases, as reflected by 39 publications in this field. Subfields of study include infectious diseases, biomedical engineering, pulmonary and respiratory medicine, molecular biology, and otorhinolaryngology.

The scientist's work is heavily centered around SARS-CoV-2 and COVID-19 research. Key research topics include SARS-CoV-2 detection and testing, COVID-19 clinical research studies, nanoplatforms for cancer theranostics, photodynamic therapy research studies, laser applications in dentistry and medicine, and ocular infections and treatments.

Recent papers authored or co-authored by Jeffrey A. Gelfand include:

  • Evaluation of SARS-CoV-2 serology assays reveals a range of test performance (2020, Nature Biotechnology)
  • Test performance evaluation of SARS-CoV-2 serological assays (2020, bioRxiv (Cold Spring Harbor Laboratory))
  • Rethinking the role of hydroxychloroquine in the treatment of COVID-19 (2020, The FASEB Journal)
  • Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital (2020, The FASEB Journal)
  • High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts (2020, The Journal of Infectious Diseases)

Their frequent co-authors include Mark C. Poznansky, Laísa Bonafim Negri, Tyler E. Miller, Diane Yang, and Michael G. Astudillo. These collaborations highlight a network engaged in diverse areas related to infectious disease research and diagnostics.

Publications by Gelfand have appeared in several key venues, with multiple papers in bioRxiv (Cold Spring Harbor Laboratory), The FASEB Journal, and The Journal of Infectious Diseases. Other publications are noted in Regular and Young Investigator Award Abstracts and Nature Biotechnology.

Jeffrey A. Gelfand has been recognized by the scientific community, having been named a Fellow of the American Association for the Advancement of Science (AAAS) in 2007 and a member of the Association of American Physicians. These honors mark involvement in ongoing professional development and contribution to medical science.

Best Publications

  • Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

    S Okusawa;J A Gelfand;T Ikejima;R J Connolly

  • Circulating Interleukin-1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever

    J.G. Cannon;R.G. Tompkins;J.A. Gelfand;H.R. Michie

  • Anticytokine Strategies in the Treatment of the Systemic Inflammatory Response Syndrome

    Charles A. Dinarello;Jeffrey A. Gelfand;Sheldon M. Wolff

  • A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits.

    Go Wakabayashi;Jeffrey A. Gelfand;John F. Burke;Robert C. Thompson

  • Persistent and relapsing babesiosis in immunocompromised patients.

    Peter J. Krause;Benjamin E. Gewurz;Benjamin E. Gewurz;David Hill;Francisco M. Marty

  • Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli.

    G Wakabayashi;J A Gelfand;W K Jung;R J Connolly

  • Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself

    Ralf Schindler;Jeffrey A. Gelfand;Charles A. Dinarello.

  • Test performance evaluation of SARS-CoV-2 serological assays

    Unknown

  • Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.

    James E. Gadek;Stephen W. Hosea;Jeffrey A. Gelfand;Maria Santaella

  • Evaluation of SARS-CoV-2 serology assays reveals a range of test performance.

    Jeffrey D. Whitman;Joseph Hiatt;Cody T. Mowery;Brian R. Shy

  • A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis.

    T Takabayashi;E Vannier;B D Clark;N H Margolis

  • C5a induction of human interleukin 1. Synergistic effect with endotoxin or interferon-gamma.

    S Okusawa;C A Dinarello;K B Yancey;S Endres

  • C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro : Comparison with secretion of interleukin-1 beta and interleukin-1 alpha

    S. Okusawa;K.B. Yancey;J.W.M. van der Meer;S. Endres

  • Acquired C1 esterase inhibitor deficiency and angioedema: a review.

    J A Gelfand;G R Boss;C L Conley;R Reinhart

  • Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro

    J. W.M. Van Der Meer;S. Endres;G. Lonnemann;Joseph Gerard Cannon

  • Circulating interleukin-1 beta and tumor necrosis factor-alpha concentrations after burn injury in humans.

    Joseph G. Cannon;Joseph S. Friedberg;Jeffrey A. Gelfand;Ronald G. Tompkins

  • Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event

    Gilles Kaplanski;Reuven Porat;Koichi Aiura;John K. Erban

  • Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.

    Yang Zeng;Binghao Li;Yingying Liang;Patrick M. Reeves

  • Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits

    E. E. Tredget;Yong Ming Yu;S. Zhong;R. Burini

  • Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

    Eric A. Meyerowitz;Augustin G. L. Vannier;Morgan G. N. Friesen;Sara Schoenfeld

  • Hereditary angioedema: The use of fresh frozen plasma for prophylaxis in patients undergoing oral surgery

    Charles J. Jaffe;John P. Atkinson;Jeffrey A. Gelfand;Michael M. Frank

  • Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital.

    Tyler E. Miller;Wilfredo F. Garcia Beltran;Adam Z. Bard;Tasos Gogakos

  • A simple method for the determination of complement receptor-bearing mononuclear cells.

    Jeffrey A. Gelfand;Anthony S. Fauci;Ira Green;Michael M. Frank

  • The immune response to trauma.

    B H Harris;J A Gelfand

Frequent Co-Authors

Mark C. Poznansky
Mark C. Poznansky Harvard University
Charles A. Dinarello
Charles A. Dinarello University of Colorado Anschutz Medical Campus
Michael M. Frank
Michael M. Frank Duke University
Michael R. Hamblin
Michael R. Hamblin University of Johannesburg
Ronald G. Tompkins
Ronald G. Tompkins Harvard University
Go Wakabayashi
Go Wakabayashi Iwate Medical University
Tianhong Dai
Tianhong Dai Harvard University
Sherwood L. Gorbach
Sherwood L. Gorbach Tufts University
Edward T. Ryan
Edward T. Ryan Harvard University
Bradley E. Bernstein
Bradley E. Bernstein Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online healthcare programs can open doors to diverse career options. These programs often provide flexible learning opportunities, making it easier to balance studies with other commitments while gaining essential medical knowledge.

If public health interests you, many institutions offer online MPH programs easy to get into, ideal for those seeking to expand their expertise in epidemiology, disease prevention, and health policy without overwhelming admission processes.

Career pathways extend beyond traditional lab roles. For example, child life specialists play a vital role in healthcare settings by supporting young patients emotionally and psychologically. Understanding how much do child life specialists make can help you evaluate this rewarding career option in the context of your goals.

Finally, it's important to note that higher education opportunities in healthcare are increasingly accessible to a diverse range of students. The best degrees for felons include several online options, highlighting the growing inclusivity and second-chance opportunities within the field.

For a comprehensive overview of available programs, consider exploring various online healthcare programs that align with your interests and career aspirations.

Best Scientists Citing Jeffrey A. Gelfand

Trending Scientists

Recently Published Articles